Curated News
By: NewsRamp Editorial Staff
April 10, 2024
Oncotelic Therapeutics Opens Enrollment for STOP-PC Clinical Trial
Discuss on Reddit
Discuss on SubstackTLDR
- Investing in Oncotelic Therapeutics may provide a competitive advantage in the growing pancreatic cancer market.
- OT-101, an anti-TGF-β RNA therapeutic, inhibits TGF-β protein to treat aggressive cancers like pancreatic cancer.
- Oncotelic Therapeutics' clinical trial for OT-101 offers hope for improving survival rates and treatment options for pancreatic cancer patients.
- The STOP-PC clinical trial aims to evaluate the effectiveness of OT-101 in combination with mFOLFIRINOX, providing an interesting opportunity for patients and researchers.
Impact - Why it Matters
The rise in early-onset pancreatic cancer rates is a concerning trend that affects not only patients but also the healthcare industry and society as a whole. The efforts of Oncotelic Therapeutics to develop more therapeutic options for pancreatic cancer could potentially improve survival rates and quality of life for patients facing this deadly disease. The STOP-PC clinical trial holds the potential to significantly impact the future treatment of pancreatic cancer.
Summary
An alarming increase in early-onset pancreatic cancer has been reported, with rates jumping almost 15% for people under 50 from 2010-2019. With a 12% five-year survival rate, pancreatic cancer is projected to become the second leading cause of cancer-related deaths in the U.S. by 2030. Oncotelic Therapeutics, a leading therapeutics company, is aiming to provide hope to pancreatic cancer patients through its lead immuno-oncology drug candidate, OT-101.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Oncotelic Therapeutics Opens Enrollment for STOP-PC Clinical Trial
